Gong-yan Chen

发表

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Jun Ma, Yi-long Wu, Q. Xiu, 2011, The Lancet. Oncology.

Expression of p300 and CBP is associated with poor prognosis in small cell lung cancer.

Gong-yan Chen, Yina Gao, J. Geng, 2014, International journal of clinical and experimental pathology.

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Jianying Zhou, Erdem Goker, Jun Zhao, 2019, The Lancet.

Preliminary results of randomized phase III study comparing efficacy and safety of first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR-activating mutations (OPTIMAL).

Yi-long Wu, Xiaole Shirley Liu, C. Zhou, 2010 .

Efficacy and Safety of Niraparib as Maintenance Treatment in Patients with Extensive-Stage Small Cell Lung Cancer after First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.

W. Wang, Jianxing He, He-long Zhang, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial

Jianxing He, R. Guo, Yong Fang, 2022, JTO clinical and research reports.

Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy

Ying Cheng, Jianxing He, R. Guo, 2020, Clinical Cancer Research.

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.

Ying Cheng, Jian-hua Chang, Yunpeng Liu, 2020, The Lancet. Respiratory medicine.

Investigation of nutritional status in Chinese patients with common cancer

Weiqi Wang, Yongdong Feng, Y. Ba, 2020, SCIENTIA SINICA Vitae.

Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study, CTONG-0904): an open-label, randomized, phase III trial

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2021, Annals of translational medicine.

Nutritional status and survival of 8247 cancer patients with or without diabetes mellitus—results from a prospective cohort study

Wenjie Zhu, Yong-mei Shi, Yongdong Feng, 2020, Cancer medicine.

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Ying Cheng, Wei Shi, Yunpeng Liu, 2022, The Lancet. Oncology.

Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma

Y. Hu, Ying Cheng, Yi-long Wu, 2020, Frontiers in Oncology.

Erlotinib Plus Capecitabine as First-Line Treatment for Older Chinese Patients With Advanced Adenocarcinoma of the Lung (C-TONG0807)

Y. Huang, Ying Cheng, Gong-yan Chen, 2015, Medicine.

A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC).

Jianxing He, Baolan Li, Changping Wu, 2016, Clinical lung cancer.

Expert consensus on multi-disciplinary treatment, whole-course pulmonary rehabilitation management in patients with lung cancer and chronic obstructive lung disease.

Yan Xu, Jie Hu, Xiaorong Dong, 2022, Annals of palliative medicine.

肺癌骨转移诊疗专家共识（2014版）

Mengzhong Liu, Qinghua Zhou, Jun Liang, 2014, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

CXCL12 suppresses cisplatin-induced apoptosis through activation of JAK2/STAT3 signaling in human non-small-cell lung cancer cells

Zhao-yang Yang, Gong-yan Chen, Yicun Wang, 2017, OncoTargets and therapy.

cXcl 12 suppresses cisplatin-induced apoptosis through activation of JaK 2 / sTaT 3 signaling in human non-small-cell lung cancer cells

Zhao-yang Yang, Gong-yan Chen, Yicun Wang, 2017 .

Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).

Yi-long Wu, Q. Xiu, Chengping Hu, 2012 .

Elevated expression of SOX 2 and FGFR 1 in correlation with poor prognosis in patients with small cell lung cancer

Gong-yan Chen, Yina Gao, J. Geng, 2013 .

Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study.

Jianxing He, Y. Shu, Yiping Zhang, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma.

M. Hung, Yun-Ju Lai, Li-Chuan Chan, 2020, American journal of cancer research.

中国肺癌脑转移诊治专家共识（2017年版）

Yang Zhang, B. Han, Jinming Yu, 2017, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.

N. Yang, Yu-Mei Shi, Shucai Zhang, 2022, The Lancet. Respiratory medicine.

The patient-generated subjective global assessment is a promising screening tool for cancer cachexia

Y. Ba, Chang Wang, Tao Li, 2020, BMJ Supportive & Palliative Care.

Current management of chemotherapy-induced neutropenia in adults: key points and new challenges

H. Yao, Ying Cheng, Bing-he Xu, 2020, Cancer biology & medicine.

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

Xiaoping Zhou, V. Miller, Siraj M. Ali, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Where are we and where to go for supportive cancer care in China? A national survey of patients and healthcare providers

Yiming Zhou, Y. Ba, T. Deng, 2021 .

Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study.

Gong-yan Chen, Yun-peng Yang, Zhehai Wang, 2022, Lung cancer.

Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer

R. Guo, Jun Zhao, S. Ren, 2021, Annals of translational medicine.

Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1‐positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE‐042 China Study

T. Mok, Yi-long Wu, Li Zhang, 2020, International journal of cancer.

Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous non-small-cell lung cancer (CameL-sq): a phase 3 trial.

Ying Cheng, R. Guo, Yiping Zhang, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

CTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC

Y. Shu, Y. Wu, N. Yang, 2019, Annals of Oncology.

Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations

He-long Zhang, N. Yang, Sanyuan Sun, 2022, JTO clinical and research reports.

Lorlatinib for Previously Treated ALK -Positive Advanced NSCLC: Primary Ef ﬁ cacy and Safety From a Phase 2 Study in People ’ s Republic of China

C. Bai, He-long Zhang, Jian-hua Chang, 2022 .

MCM2 is a therapeutic target of lovastatin in human non-small cell lung carcinomas.

L. Ye, Gong-yan Chen, Yina Gao, 2015, Oncology reports.

MCM 2 is a therapeutic target of lovastatin in human non-small cell lung carcinomas

Gong-yan Chen, Yina Gao, Xuan Hong, 2015 .

Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.

Ying Cheng, He-long Zhang, N. Yang, 2021, The Lancet. Respiratory medicine.

Expression of p 300 and CBP is associated with poor prognosis in small cell lung cancer

Gong-yan Chen, Yina Gao, J. Geng, 2014 .

Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.

Yi-long Wu, Jian-hua Chang, Dong Wang, 2022, The Lancet. Oncology.

Ef ﬁ cacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study

Ying Cheng, R. Guo, Yiping Zhang, 2022 .

Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non‐small‐cell lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapy

Tao Zhang, Wei Shi, Jian-hua Chang, 2022, Cancer communications.

Peripheral Tumor Location Predicts a Favorable Prognosis in Patients with Resected Small Cell Lung Cancer

Gong-yan Chen, Yina Gao, Xuan Hong, 2022, International journal of clinical practice.

Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)

Jianxing He, H. Qin, Gong-yan Chen, 2022, Frontiers of Medicine.

Treatment Pattern and Overall Survival of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Multicentric Real-World Study in China (CTONG1506)

Yi-long Wu, P. Yu, D. Zhong, 2020 .

Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small-cell lung cancer: results from a randomized, double-blind, phase 3 trial (ORIENT-12).

Baolan Li, Chengping Hu, P. Sun, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Third‐line or above anlotinib in relapsed and refractory small cell lung cancer patients with brain metastases: A post hoc analysis of ALTER1202, a randomized, double‐blind phase 2 study

H. Qin, Gong-yan Chen, Qiming Wang, 2023, Cancer innovation.

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2021, Cancer cell.

Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Non-squamous NSCLC in the Phase III ORIENT-11 Study.

Baolan Li, Wei-min Li, B. Peng, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial

Ying Cheng, R. Guo, Sheng Hu, 2022, Molecular cancer.

Clinical Characteristics Correlate With Outcomes of Immunotherapy in Advanced Non-Small Cell Lung Cancer

Zhao-yang Yang, Gong-yan Chen, Yina Gao, 2020, Journal of Cancer.

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.

H. Zhang, Yi-long Wu, B. Han, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

STAT5a-targeting miRNA enhances chemosensitivity to cisplatin and 5-fluorouracil in human colorectal cancer cells.

Yanqiao Zhang, Gong-yan Chen, Xuan Hong, 2012, Molecular medicine reports.

Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma

Jianxing He, Guangfa Wang, Junling Li, 2021, Theranostics.

Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study

Y. Liu, Ying Cheng, B. Han, 2021, British Journal of Cancer.

Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors:  Safety, Efficacy, and Biomarkers

Jianxing He, Baorui Liu, Jian-hua Chang, 2022, The oncologist.

Significance of survivin expression: Prognostic value and survival in stage III non-small cell lung cancer.

Zhao-yang Yang, Gong-yan Chen, Xuan Hong, 2012, Experimental and therapeutic medicine.

Bevacizumab Plus Erlotinib in Chinese Patients with Untreated, EGFR-Mutated, Advanced NSCLC (ARTEMIS-CTONG1509): A Multicenter Phase 3 Study

Ying Cheng, Yi-long Wu, Zhi-yong Ma, 2020 .

Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11).

Ying Cheng, B. Han, Baolan Li, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer

Yi-long Wu, Jin-Ji Yang, Jianxing He, 2020, Investigational New Drugs.

Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first‐line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open‐label, parallel controlled clinical study

J Zhang, Jianxing He, Guangfa Wang, 2021, Cancer communications.

A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002).

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2019, European journal of cancer.

A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2014, Lung cancer.

Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2017, The Lancet. Respiratory medicine.

China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version)

D. Lin, B. Han, Changli Wang, 2017, Asia-Pacific journal of clinical oncology.

中国埃克替尼治疗非小细胞肺癌专家共识（2016年版）

B. Han, Jianxing He, Y. Ling, 2016, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version).

B. Han, C. Bai, Jianxing He, 2015, Journal of Thoracic Disease.

China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version).

B. Han, C. Bai, Jianxing He, 2015, Journal of thoracic disease.

中国埃克替尼治疗非小细胞肺癌专家共识(2015版)

B. Han, Jianxing He, Y. Ling, 2015, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Ef ﬁ cacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study

He-long Zhang, Baolan Li, Yu-Mei Shi, 2022 .

[Expression of hTERT mRNA in Anip973 and Anip973/NVB cell detected by quantitative real-time PCR].

Jingjing Liu, Gong-yan Chen, Shuying Guo, 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Multidrug resistance-associated protein 3 and Bcl-2 contribute to multidrug resistance by vinorelbine in lung adenocarcinoma.

X. Hao, Zhao-yang Yang, Gong-yan Chen, 2011, International journal of molecular medicine.

Ying Cheng, Baolan Li, Yunpeng Liu, 2019, Translational lung cancer research.

Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial

Ying Cheng, Jianxing He, H. Qin, 2021, Cancer medicine.

A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel

Ying Cheng, Yi-long Wu, B. Han, 2017, ESMO Open.

A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)

P. Yu, Xin Zhang, Yi Hu, 2017, BMC Cancer.

人肺腺癌Anip973/NVB耐药细胞系动物模型的建立及其耐药机制的研究

Zhao-yang Yang, Gong-yan Chen, Xuan Hong, 2012, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Survey and analysis of the nutritional status in hospitalized patients with malignant gastric tumors and its influence on the quality of life

Yong-mei Shi, Yongdong Feng, Y. Ba, 2019, Supportive Care in Cancer.

The value of prognostic factors in Chinese patients with small cell lung cancer: A retrospective study of 999 patients

Zhao-yang Yang, Gong-yan Chen, Yina Gao, 2018, The clinical respiratory journal.

Nutritional assessment and risk factors associated to malnutrition in patients with esophageal cancer.

Yongdong Feng, Y. Ba, Chang Wang, 2020, Current problems in cancer.

Lorlatinib for Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer: Primary Efficacy and Safety From a Phase 2 Study in China.

Ying Cheng, C. Bai, He-long Zhang, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3‐day aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study

Jian-hua Chang, Wei Li, Dong Wang, 2020, Cancer medicine.

Efficacy of PD-1 monoclonal antibody SHR-1210 plus apatinib in patients with advanced nonsquamous NSCLC with wild‐type EGFR and ALK.

Yi Na Wang, Ying Cheng, Jianxing He, 2019, Journal of Clinical Oncology.

A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)

Yi-long Wu, P. Yu, Yiping Zhang, 2017, BMC Cancer.

Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies.

T. Wang, D. Zhong, Yanqiu Zhao, 2023, Lung cancer.

Ef ﬁ cacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/ Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study

T. Wang, D. Zhong, Yanqiu Zhao, 2022 .

P-645 A randomized trial comparing neoadjuvant gemicitabine plus carboplatin or cisplatin followed by surgery with surgery alone in Clinical Stage IIIA non-small-cell lung cancer (NSCLC)

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2005 .

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial Study

R. Guo, Yiping Zhang, Wei Zhang, 2022 .

Investigation on nutrition status and clinical outcome of patients with common cancers in Chinese patients: a multicenter prospective study protocol

Yongdong Feng, Y. Ba, Chang Wang, 2020 .

Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study

Ying Cheng, Yulan Sun, Sanyuan Sun, 2022, Therapeutic advances in medical oncology.

Abstract CT038: Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage SCLC: A phase 3 trial

Baolan Li, Huiqing Yu, Chengping Hu, 2022, Cancer Research.

Elevated expression of SOX2 and FGFR1 in correlation with poor prognosis in patients with small cell lung cancer.

Gong-yan Chen, Yina Gao, J. Geng, 2013, International journal of clinical and experimental pathology.

An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870)

Changli Wang, Jian-hua Chang, Baocheng Wang, 2022, Therapeutic advances in medical oncology.

Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC)

Y. Liu, Ying Cheng, Juxian Wang, 2019, Annals of Oncology.

Safety, Efficacy and Pharmacokinetics of Rezivertinib (BPI-7711) in Advanced Non-Small Cell Lung Cancer Patients with EGFR T790M Mutation: a Phase 1 Dose-Escalation and Dose-Expansion Study.

Yanqiu Zhao, Y. Shu, Gong-yan Chen, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506).

Yi-long Wu, P. Yu, Yiping Zhang, 2018, Lung cancer.

Effectiveness of anlotinib in patients with small‐cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study

Y. Liu, Ying Cheng, B. Han, 2021, Thoracic cancer.

A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management

S. Gambhir, Zhen Cheng, B. Shen, 2018, Science Translational Medicine.

Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study

Ying Cheng, Yulan Sun, Sanyuan Sun, 2022, Therapeutic advances in medical oncology.

OA13.03 Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, Double-Blind Phase 2 Trial

Xia Li, Ying Cheng, B. Han, 2018, Journal of Thoracic Oncology.

A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens.

Yiping Zhang, Cheng Huang, Xiaoqing Liu, 2012 .

MA14.05 A Randomized Phase III Trial of Fruquintinib Versus Placebo in Patients with Advanced Non-Small Cell Lung Cancer (FALUCA)

Ying Cheng, C. Bai, Jin-Ji Yang, 2019, Journal of Thoracic Oncology.

Single-arm, phase II study of pyrotinib in advanced non-small cell lung cancer (NSCLC) patients with HER2 exon 20 mutation.

Jianxing He, Y. Shu, Yiping Zhang, 2019, Journal of Clinical Oncology.

Abstract CT158: ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboringMET exon 14skipping alterations (METex14)

Ying Cheng, Yulan Sun, Sanyuan Sun, 2021, Clinical Trials.